Navigation Links
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Date:5/12/2008

t of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 Die ... – Bei der englischen Version ... , 91 % der Teilnehmer einer groß angelegten Asthmaumfrage ... % laut GINA [*] -Definition [1] als kontrolliert ... mit Asthma generell einer von vier Denkweisen zugeordnet werden ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... 2013 Can economic incentives such as ... members of the public to increase their donations of ... Hopkins Carey Business School Assistant Professor Mario Macis ... a large body of recent research that supports their ... 2013, issue of Science that the World Health Organization ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... - Novel system is the first to use rapid, automated ... ... eGenomics, Inc., a leader in the,development of state of the ... that the United States Patent,and Trademark Office (USPTO) recently issued ...
... /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC Bulletin ... of plant extracts and pharmaceutical raw,materials for use ... is pleased to announce a Letter of Intent ... Xintong Medical Ltd. ("Qinba").,Under the proposed terms of ...
... Mass., Sept. 4 Hologic, Inc.,(Nasdaq: HOLX ) ... presenting at the Morgan Stanley Global Healthcare Unplugged,Conference being ... in New,York, NY., Interested parties are invited to ... on Tuesday, September 9, 2008, at 1:35 PM.,Eastern Time ...
Cached Biology Technology:eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 2eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 3Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:5/22/2013)... omega 3 fatty acids in fish oil have long ... that the American Heart Association currently recommends eating at ... varieties rich in omega 3s. However, the mechanism behind ... new study, scientists led by Jason R. Carter of ... providing evidence that fish oil might specifically counteract the ...
(Date:5/22/2013)... endanger the whole organism, as they may lead to ... Munich now report how byproducts of respiration cause mispairing ... in our cells controls the form and function of ... this are encoded in the linear sequence of the ... cytosine (C), guanine (G) and thymine (T). Random changes ...
(Date:5/22/2013)... for prostate cancer could become as easy for men ... UC Irvine research published today in the Journal ... than a decade of work, UC Irvine chemists have ... for prostate cancer in urine, meaning that the disease ... at dramatically lower cost. The same technology could potentially ...
Breaking Biology News(10 mins):Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... biologists, the ability to capture high-quality, three-dimensional (3D) images ... to answer problems in areas ranging from genomics to ... more detailed the information that can be drawn from ... researchers from the California Institute of Technology (Caltech) have ...
... built by Cleveland researchers has reached efficiencies akin to the ... man-made lungs require - for the source of the essential ... for the 200 million lung disease sufferers worldwide, the device ... implantable artificial lung, said Joe Potkay, a research assistant professor ...
... − Famous for their sluggishness, turtles have been slow ... place on the evolutionary tree. For decades, paleontologists who ... disagreed about whether turtles are more closely related to ... from the Mount Desert Island Biological Laboratory in Bar ...
Cached Biology News:Sharper, deeper, faster 2Sharper, deeper, faster 3Artificial lung mimics real organ's design and efficiency 2Discovery places turtles next to lizards on family tree 2
...
...
... Complete Derivation Kit is intended for ... from delayed blastocysts in serum-free conditions. ... Clonal Grade Medium ... Incubation Medium Trypsin Solution Gelatin ...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Biology Products: